Martin David Harp, Editor, Ophthalmology Times

Susvimo is the first and only FDA-approved, continuous delivery treatment shown to maintain vision in people with DR with just one refill every 9 months

NCX 470, Nicox’s lead clinical product candidate, is a novel NO-donating bimatoprost eye drop with a dual mechanism of action (nitric oxide and prostaglandin analogue).

At ARVO 2025, Mark Bullimore, MCOptom, PhD, emphasized the need for more accurate, condition-specific tools in evaluating myopic eye growth and treatment efficacy.

Hammond and his team focused on creating a reliable conversion factor between 2 widely used optical coherence tomography (OCT) systems—the TopCon Maestro2 and the ZEISS Cirrus 5000. Their work specifically looked at ganglion cell–inner plexiform layer and retinal nerve fiber layer thickness measurements, which are critical markers in glaucoma diagnosis and monitoring.

The FDA did not agree with a supplemental Biologics License Application for the addition of extended dosing intervals of up to 24 weeks across currently-approved indications.

A survey collected demographic data, ocular and medical history, and responses assessing knowledge of glaucoma and cataracts in the Qassim region of Saudi Arabia.

The supplemental BLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion and for broadening the dosing schedule to include every-4-week dosing across approved indications.

The announcement follows the decision to discontinue the COAST and ShORe trials in wet age-related macular degeneration after the COAST trial failed to meet its primary end point.

A Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025, was set by the organization.

Pantheon Vision’s bioengineered corneal implant aims to tackle issues with the success rate of human donated tissue.

The company stated that the FDA noted at least one additional adequate and well controlled study to demonstrate a positive effect on the treatment of ocular symptoms of dry eye should be conducted.

The decision to discontinue the trials comes shortly after the announcement that COAST missed its primary endpoint.

Lab TRIACTIV is powered by “advanced cationic liposomal technology” for dry eye relief and targets all 3 layers of the tear film.

In light of trial results, the company is preparing for financial outcomes dependent on its Development Funding Agreement, warranting a reexamination of Opthea's future.

Urcosmod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor, typically found on immune cells of the eye responsible for the inflammatory response.

ENCELTO is the first and only FDA-approved treatment for MacTel.

If approved, Epoxia will be the first epi-on corneal crosslinking on the market.

At the Envision Summit 2025 in San Juan, Puerto Rico, Sherrol Reynolds, OD, FAAO, participated in a discussion on patient-centered care and the newest treatment strategies in neovascular AMD and DME.

At the Envision Summit 2025 in San Juan, Puerto Rico, Ashley Wallace Tucker, OD, FAAO, FSLS, gave insight into advancements in keratoconus management and the importance of early detection as well as tips and advice on fitting scleral contact lens

At the Envision Summit 2025 in San Juan, Puerto Rico, Jessica Steen, OD, FAAO talked with glaucoma surgeons on the importance of comanaging patients throughout their lifetime.

The Sentinel Camera aims to address critical gaps in retinal disease screening by offering a portable device that captures high-quality images that require no dilation of the eye.

Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a one-time, outpatient procedure, continuously delivering a customized formulation of ranibizumab over time.

Results from the study assisted Notal Vision in receiving De Novo authorization from the US FDA for the SCANLY Home OCT in 2024.

Results showed that at 6 months post-surgery, at least 1-, 2-, and 3-line gains in best-corrected distance were achieved in 97.1%, 68.6%, and 51.4% of operated eyes, respectively.

Whitecap is currently developing 2 therapies for potential use in glaucoma and geographic atrophy.

The campaign will spotlight educational resources and share stories of individuals and families living with glaucoma to raise awareness and encourage proactive eye health management.

The primary safety endpoint was carried out through the percentage of patients with shift from normal (at baseline) to abnormal in any electrocardiogram (ECG).

A look at the biggest news and advancements in ophthalmology in 2024.

Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.